RISK-1: a novel MAPK homologue in axoplasm that is activated and retrogradely transported after nerve injury.
Sensory neurons (SNs) of Aplysia are widely used to study the molecular correlates of learning. Among these is the activation of an Aplysia (ap) MAPK that phosphorylates the transcription factor apC/EBPbeta. Because crushing the axons of the SNs induces changes similar to learning, we tested the hypothesis that apMAPK is a point of convergence on the pathways for learning and injury. One event in common is long-term hyperexcitability (LTH), and LTH was induced in the SNs after intrasomatic injection of active vertebrate extracellular signal-regulated kinase 1 (ERK1; as an apMAPK surrogate). Nerve crush activated an axoplasmic kinase at the site of injury that phosphorylated apC/EBPbeta. Surprisingly, this was not apMAPK, but a kinase that was recognized by antibodies to vertebrate ERKs and to doubly phosphorylated, activated ERKs. The activated kinase was transported to the cell body and nucleus and its arrival was concurrent with an injury-induced increase in apC/EBPbeta mRNA and protein. We call this retrogradely transported kinase RISK-1. RISK-1 initiated the binding of apC/EBPbeta to the ERE enhancer site in vitro and an increase in ERE-binding was detected in injured neurons containing active RISK-1. Thus, Aplysia neurons contain two MAPK homologues, one of which is a late acting retrogradely transported injury signal.
Anatomy and Cell Biology, College of Physicians and Surgeons, Columbia University, 1204 Black Building, W. 168th Street, New York, NY 10032, USA.
Y J
YJ
Sung
M
M
Povelones
R T
RT
Ambron
D000818:Animals; D001048:Aplysia; D001370:Axonal Transport / Q000502:physiology*; D001369:Axons / Q000201:enzymology*; D022782:CCAAT-Enhancer-Binding Protein-beta / Q000235:genetics / Q000378:metabolism; D066298:In Vitro Techniques; D007858:Learning / Q000502:physiology; D017774:Long-Term Potentiation / Q000502:physiology; D008845:Microinjections; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism*; D009409:Nerve Crush; D009475:Neurons, Afferent / Q000166:cytology / Q000187:drug effects / Q000201:enzymology; D010766:Phosphorylation; D012333:RNA, Messenger / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology
D022782:CCAAT-Enhancer-Binding Protein-beta; D012333:RNA, Messenger; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases; C426604:RISK-1 kinase, Aplysia